Future Challenges in Cancer Resistance to Immunotherapy

Cancer immunotherapies, including checkpoint inhibitors, adoptive T cell transfer and therapeutic cancer vaccines, have shown promising response rates in clinical trials. Unfortunately, there is an increasing number of patients in which initially regressing tumors start to regrow due to an immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: van Elsas, Marit J., van Hall, Thorbald, van der Burg, Sjoerd H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226490/
https://www.ncbi.nlm.nih.gov/pubmed/32290124
http://dx.doi.org/10.3390/cancers12040935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226490/
https://www.ncbi.nlm.nih.gov/pubmed/32290124
http://dx.doi.org/10.3390/cancers12040935

Ejemplares similares